1. Home
  2. REVB vs BYAH Comparison

REVB vs BYAH Comparison

Compare REVB & BYAH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Revelation Biosciences Inc.

REVB

Revelation Biosciences Inc.

HOLD

Current Price

$1.47

Market Cap

5.1M

Sector

Health Care

ML Signal

HOLD

Logo Park Ha Biological Technology Co. Ltd. Ordinary Shares

BYAH

Park Ha Biological Technology Co. Ltd. Ordinary Shares

N/A

Current Price

$0.06

Market Cap

5.3M

ML Signal

N/A

Company Overview

Basic Information
Metric
REVB
BYAH
Founded
2020
2016
Country
United States
China
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Package Goods/Cosmetics
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
5.1M
5.3M
IPO Year
N/A
2024

Fundamental Metrics

Financial Performance
Metric
REVB
BYAH
Price
$1.47
$0.06
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
1.9M
37.1M
Earning Date
03-05-2026
02-24-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$2,768,120.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
42.65
52 Week Low
$1.41
$0.05
52 Week High
$54.48
$41.49

Technical Indicators

Market Signals
Indicator
REVB
BYAH
Relative Strength Index (RSI) 54.67 30.67
Support Level $1.43 $0.05
Resistance Level $1.63 $0.11
Average True Range (ATR) 0.20 0.02
MACD -0.02 -0.00
Stochastic Oscillator 54.05 8.08

Price Performance

Historical Comparison
REVB
BYAH

About REVB Revelation Biosciences Inc.

Revelation Biosciences Inc is a clinical-stage life science company that is focused on rebalancing inflammation to optimize health using its proprietary formulation Gemini. It is developing a pipeline of potential high-value products based on Gemini. Gemini is Revelation's proprietary formulation of phosphorylated hexaacyl disaccharide (PHAD) an established TLR4 agonist that can stimulate the human body's innate immune response to prevent and treat disease. The product candidates are developed are based on Gemini formulation of PHAD. Gemini-based programs consist of: Gemini-SSI developed for the prevention of surgical site infection (SSI); Gemini-AKI developed for the prevention of acute kidney injury (AKI); and Gemini-CKD for the treatment of chronic kidney disease (CKD).

About BYAH Park Ha Biological Technology Co. Ltd. Ordinary Shares

Park Ha Biological Technology Co Ltd is engaged in developing its private skincare label, direct skincare products sales and franchise alliances promotions. Its Park Ha brand focuses on providing solutions for problematic skin. The company's Operating Subsidiaries provide skincare and cosmetic products under its brand, Park Ha in China. Its Operating Subsidiaries develop its proprietary beauty products and offer complimentary after-sales beauty services in its physical stores.

Share on Social Networks: